Your browser is not supported. Please upgrade to a modern browser in order to use all the features of the UKHC web application: Firefox | Chrome | Microsoft Edge
Skip to main content
close menu
close menu

Search UK HealthCare

Chronic Lymphocytic Leukemia (CLL) targeted therapy

Targeted drugs, often paired with chemotherapy, are designed to take advantage of the specific vulnerabilities of your cancer cells. Your cancer cells are tested to determine which targeted drugs may be helpful.

The most common targeted therapy drugs used are:

  • Rituximab (Rituxan)®
  • Alemtuzumab (Campath)®
  • Ofatumumab (Arzerra)®
  • Obinutuzumab (Gazyva)®
  • Ibrutinib (Imbruvica)®
  • Idelalisib (Zydelig)®
  • Venetoclax (Venclexta)®

Rituximab, ofatumumab and obinutuzumab are given intravenously. Alemtuzumab is given either intravenously or by an injection just under the skin. Ibrutinib is given as a capsule by mouth. Idelalisib and venetoclax are given as a tablet by mouth.